Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to -$38.6 million.

  • Orchestra BioMed Holdings' Cash from Investing Activities fell 702710.95% to -$38.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.0 million, marking a year-over-year decrease of 12596.76%. This contributed to the annual value of $13.1 million for FY2024, which is 2247.59% up from last year.
  • Orchestra BioMed Holdings' Cash from Investing Activities amounted to -$38.6 million in Q3 2025, which was down 702710.95% from $16.4 million recorded in Q2 2025.
  • Orchestra BioMed Holdings' Cash from Investing Activities' 5-year high stood at $33.2 million during Q4 2023, with a 5-year trough of -$63.4 million in Q4 2022.
  • Moreover, its 4-year median value for Cash from Investing Activities was $557000.0 (2024), whereas its average is -$3.3 million.
  • Examining YoY changes over the last 5 years, Orchestra BioMed Holdings' Cash from Investing Activities showed a top increase of 587991.07% in 2023 and a maximum decrease of 9251489.36% in 2023.
  • Quarter analysis of 4 years shows Orchestra BioMed Holdings' Cash from Investing Activities stood at -$63.4 million in 2022, then soared by 152.31% to $33.2 million in 2023, then crashed by 111.32% to -$3.8 million in 2024, then plummeted by 928.08% to -$38.6 million in 2025.
  • Its Cash from Investing Activities stands at -$38.6 million for Q3 2025, versus $16.4 million for Q2 2025 and $13.0 million for Q1 2025.